Literature DB >> 2969239

Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells.

M N Pollak1, C Polychronakos, S Yousefi, M Richard.   

Abstract

Studies of binding of IGF-I to a plasma-membrane-enriched subcellular fraction prepared from MCF-7 human breast cancer cells reveal the presence of 0.2 pmols specific binding sites for this mitogen per mg membrane protein, with an equilibrium affinity constant of 1.45 nM-1. Competition studies with insulin, IGF-II, and an anti-IGF-I receptor antibody are consistent with the presence of specific IGF-I receptors, and SDS-PAGE showed binding to a 130 kDa subunit identical to that of receptors from human placenta. In addition, we show that IGF-I is more potent than estradiol and comparable to EGF in stimulating in vitro proliferation of MCF-7 cells, and that IGF-I-stimulated proliferation of these cells is inhibited by a blocking monoclonal antibody against the IGF-I receptor. These results demonstrate that IGF-I is an important mitogen for MCF-7 cells and that the mitogenic effect is mediated by specific IGF-I receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969239     DOI: 10.1016/0006-291x(88)90688-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Elevated circulating IGF-I promotes mammary gland development and proliferation.

Authors:  Dara Cannata; Danielle Lann; Yingjie Wu; Sebastien Elis; Hui Sun; Shoshana Yakar; Deborah A Lazzarino; Teresa L Wood; Derek Leroith
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

Review 2.  Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action.

Authors:  E A Woltering; J C Watson; R C Alperin-Lea; C Sharma; E Keenan; D Kurozawa; R Barrie
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Elevated insulin receptor content in human breast cancer.

Authors:  V Papa; V Pezzino; A Costantino; A Belfiore; D Giuffrida; L Frittitta; G B Vannelli; R Brand; I D Goldfine; R Vigneri
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  Observations on the effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin Like Growth Factor I (IGF-I).

Authors:  W Sasi; L Ye; W G Jiang; K Mokbel; A Sharma
Journal:  Clin Transl Oncol       Date:  2013-09-18       Impact factor: 3.405

5.  Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status.

Authors:  R E Favoni; A de Cupis; A Perrotta; S Sforzini; D Amoroso; F Pensa; L Miglietta
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines.

Authors:  M Iwamura; M Ishibe; P M Sluss; A T Cockett
Journal:  Urol Res       Date:  1993-01

7.  Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.

Authors:  T Yano; E Korkut; J Pinski; K Szepeshazi; S Milovanovic; K Groot; R Clarke; A M Comaru-Schally; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 8.  Tamoxifen reduces serum insulin-like growth factor I (IGF-I).

Authors:  M N Pollak; H T Huynh; S P Lefebvre
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 9.  Type 1 IGF receptor in human breast diseases.

Authors:  J P Peyrat; J Bonneterre
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 10.  Progestin regulation of insulin and insulin-like growth factor I receptors in cultured human breast cancer cells.

Authors:  I D Goldfine; V Papa; R Vigneri; P Siiteri; S Rosenthal
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.